Elon Musk says fasting and Wegovy help him appear “fit, ripped, and healthy.”
Elon Musk, 51, revealed his secret to a fan who remarked he looked “great” and asked whether he was training weights and eating well.
The business magnate credited Novo Nordisk’s semaglutide brand, Wegovy. Twitter: “Fasting” Wegovy.
Elon Musk stated that his secret to looking “fit, ripped, and healthy” is fasting and the famous weight-loss medicine Wegovy.
Elon Musk, 51, disclosed his secret on Twitter earlier this month to a fan who complimented him on his “amazing” appearance and asked whether he was doing weights and eating well.
The business entrepreneur attributed his physique to Wegovy, a brand of semaglutide manufactured by Novo Nordisk. “Fasting” was his tweet—also Wegovy.
Must read: Erica Banks Before Plastic Surgery: How Does She Look After Plastic Surgery?
The once-weekly injection was initially intended for diabetic treatment but received FDA approval for “chronic weight management” last summer.
It suppresses appetite by harmonizing the body’s hunger hormones and slowing digestion. It has resulted in a 15% to 20% weight reduction over 68 weeks, as previously reported by Insider’s Gabby Landsverk.
Although the medicine is only approved for weight reduction in those with an “obese” body mass index, as well as those who are “overweight” and have a disease such as a type 2 diabetes or high cholesterol, people are paying to take it off-label, resulting to prescription shortages.
Variety said that some of these individuals are believed to be other celebrities who can afford the $1,200 to $1,500 monthly fee.
Must read: Laci J Mailey Weight Gain: Is She Expecting A Child In 2024?
Semaglutide is designed to be taken in conjunction with a reduced-calorie diet (which the medicine facilitates) and increased physical exercise, according to the FDA. Nausea and diarrhea are the most prevalent gastrointestinal adverse effects.
Elon Musk Weight Loss
Elon Musk recently revealed on his preferred social media platform Twitter that fasting and the obesity medicine Wegovy (semaglutide) from Novo Nordisk were responsible for his recent weight reduction.
Elon Musk disclosed in answer to a query he got on the social networking site, which he is due to acquire following a lengthy court fight, about his secret to looking “amazing, fit, ripped, and healthy,” stating that “Fasting” helped him lose weight “And Wegovy.”
Novo Nordisk received approval for Wegovy from the US Food and Drug Administration (FDA) last summer for chronic weight management in adults with obesity (BMI30) or who are overweight with at least one weight-related condition (such as high blood pressure, Type 2 diabetes, or high cholesterol) and a BMI of 27 or higher.
Given that the prescription is designed for patients with obesity and strict BMI criteria, it is unclear if Elon Musk should even be taking the medication, making his endorsement dubious.
According to Insider, “these types of surprise endorsements may be a double-edged sword for businesses.”
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist initially created and authorized for managing diabetes, with Novo offering two formulations of the drug (Ozempic and Rybelsus). GLP-1 is implicated in appetite and calorie intake control.
Wegovy is a higher-dose injectable formulation of semaglutide developed by Novo Nordisk for chronic weight control.
Wegovy lowers hunger and slows digestion by interacting with the GLP-1 receptor. In 68 weeks, it has been demonstrated to cause a 15% to 20% reduction in body weight.
Elon Musk is unaffiliated with Novo Nordisk, and a company spokeswoman told Fierce Pharma Marketing, “we were unaware of Elon Musk’s use of Wegovy before he made this information public.”
Must read: Did Chloe Grace Moretz Plastic Surgery 2024? The Untold Truth!
Eli Lilly has applied to the FDA for its weight reduction medicine, tirzepatide, marketed under the trade name Mounjaro. The medication was authorized to treat Type 2 diabetes in May of this year.
The obesity medicine market is projected to reach $54 billion by 2030, representing a rising pharmaceutical sector. According to Morgan Stanley Research, treating obesity might become one of the top twelve worldwide therapies. In only the previous year, Wegovy’s revenues exceeded $1.2 billion.
Diabetes drugs repurposed as obesity treatments (along with diet and exercise in most cases) not only target weight (along with diet and exercise in most cases), but an increasing number of studies indicate that they can also reduce the risk of heart attacks, strokes, and cardiovascular deaths by up to 17 percent.
His social media accounts are: Twitter.
